MGNX News and Press, MacroGenics Inc. From 04/25/22

ROCKVILLE, MD, April 25, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financia...

Citi has upgraded MacroGenics (MGNX -3.4%) to buy from neutral saying the company's pipeline has "entered undervalued territory." However, the firm cut its target price to $21 from $23 (~117% upside based on Friday's close). Analyst Yigal Nochomovitz noted that the company's focus on MGC018 f...

MacroGenics (NASDAQ:MGNX) has promoted Eric Risser to the newly created position of Chief Operating Officer. Risser, who joined the biopharmaceutical company in 2009, was previously promoted to Senior Vice President, Business Development and Portfolio Management and Chief Business Officer in ...

ROCKVILLE, MD, Feb. 28, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, announced today that it has promoted Eric Risser to Chief Operating Of...

100s of companies run trials in Ukraine; some of them will face delays. In the long term, Ukraine may cease to be a favored location for clinical trials. However, neither Russia nor Ukraine are drug manufacturing hubs, and market exposure is minimal. For further details see:...

Shares of MacroGenics (NASDAQ: MGNX) had sunk 13.4% lower at 10:50 a.m. ET on Friday. The decline came after the biopharmaceutical company provided its fourth-quarter update following the market close on Thursday. MacroGenics announced only its 2021 full-year results. Howev...

MGNX has an approved drug that isn't doing too well. OS data for the drug in the approved indication was poor. The company is not adequately derisked right now. For further details see: MacroGenics: Facing Considerable Headwinds From Unsatisfactory Trials

Image source: The Motley Fool. MacroGenics (NASDAQ: MGNX) Q4 2021 Earnings Call Feb 24, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: MacroGenics (MGNX) Q4 2021 Earnings Call Transcript

MacroGenics, Inc. (MGNX) Q4 2021 Results Conference Call February 24, 2022 04:30 PM ET Company Participants Christopher James - Vice President of Investor Relations and Corporate Communications Scott Canning - President and Chief Executive Officer James Karrels - Senior Vice President and Chi...

MacroGenics press release (NASDAQ:MGNX): FY GAAP EPS of -$3.37 misses by $0.10. Revenue of $77.45M (-26.2% Y/Y) misses by $6.13M. For further details see: MacroGenics GAAP EPS of -$3.37 misses by $0.10, revenue of $77.45M misses by $6.13M